SOM Biotech

Moderna mRNA-1083 Phase 3 data show stronger flu and COVID immune response

FDA · COVID-19 · 6 min

Moderna says its combined flu-COVID vaccine mRNA-1083 met Phase 3 primary endpoints with higher immune responses in adults 50 and older. The readout matters for BD teams and investors tracking combo-vaccine competition, FDA posture, and next filing milestones.

Moderna Stock Rises as EMA Committee Backs New RSV Vaccine: Key Implications for Investors and BD Teams

EMA · 5 min

Moderna Inc. stock (MRNA) rose 5.9% after an EMA committee backed its new RSV vaccine candidate. This analysis explains what changed, why it matters for pharma BD and investors, and what to watch next.

Biotech's Future: Insights from Jeremy Levin

FDA · 8 min

Structured plan for Biotech's Future: Insights from Jeremy Levin

Biotech Movers: Moderna, Iovance, ALHC, and Summit Therapeutics in Focus

Ebola · 6 min

Biotech stocks showed mixed performance as Moderna advanced its Ebola vaccine efforts and Summit Therapeutics saw a surge on Phase 3 data. Meanwhile, Alignment Healthcare faced a downgrade, and Iovance Biotherapeutics remains a subject of analyst debate.

Astellas Cuts Costs Amid FDA Review of Moderna Vaccine

FDA · 3 min

Astellas Pharma is implementing cost reductions as the FDA panel prepares to review the Moderna vaccine. This article explores the implications for the pharmaceutical industry.